Clinical Protocol and Data Management

$485,600P30FY2025CANIH

University Of Pittsburgh At Pittsburgh, Pittsburgh PA

Investigators

Linked publications & trials

Paper 39691513 Paper 39673591 Paper 39656513 Paper 39587886 Paper 39574596 Paper 39551606 Paper 39509271 Paper 39478577 Paper 39461879 Paper 39455577 Paper 39445806 Paper 39438602 Paper 39437546 Paper 39428608 Paper 39409894 Paper 39407274 Paper 39386586 Paper 39386568 Paper 39385301 Paper 39379043 Paper 39372673 Paper 39329526 Paper 39316409 Paper 39312740 Paper 39308168 Paper 39304063 Paper 39297647 Paper 39281316 Paper 39271688 Paper 39269437 Paper 39264275 Paper 39259704 Paper 39244563 Paper 39240167 Paper 39229010 Paper 39207954 Paper 39191946 Paper 39189448 Paper 39172160 Paper 39169038 Paper 39167743 Paper 39167740 Paper 39156821 Paper 39137006 Paper 39127839 Paper 39121849 Paper 39121848 Paper 39114979 Paper 39114667 Paper 39113675 Paper 39106585 Paper 39086481 Paper 39078429 Paper 39075526 Paper 39074819 Paper 39067022 Paper 39066414 Paper 39055715 Paper 39054343 Paper 39049849 Paper 39044072 Paper 39042692 Paper 39039662 Paper 39033157 Paper 39026889 Paper 38984983 Paper 38955184 Paper 38938748 Paper 38936937 Paper 38934706 Paper 38932182 Paper 38920634 Paper 38917692 Paper 38898383 Paper 38896611 Paper 38886411 Paper 38883769 Paper 38874417 Paper 38848131 Paper 38832925 Paper 38824190 Paper 38812549 Paper 38809988 Paper 38807270 Paper 38804084 Paper 38783541 Paper 38775415 Paper 38757942 Paper 38743253 Paper 38714889 Paper 38682653 Paper 38674756 Paper 38658775 Paper 38645178 Paper 38638689 Paper 38627362 Paper 38626341 Paper 38621193 Paper 38599298 Paper 38596718

Abstract

Abstract: Clinical Protocol and Data Management (CPDM) Clinical Protocol and Data Management (CPDM) at the UPMC Hillman Cancer Center (HCC) is supported by the Department of Clinical Research Services (CRS). CRS facilitates the development, implementation, coordination, internal data monitoring, and completion of both pediatric and adult oncology-focused trials. CRS supports national, external peer-reviewed, institutional, and industry trials at all phases, involving all treatment modalities, with 413 active trials in 2018, including 266 early phase (Pilot, Phase 1/2), 72 Investigator-Initiated Trials (IITs) of which 43 are developed by HCC investigators, and 96 national trials (DT4). HCC accrued 1,843 patients on interventional trials of whom 745 were on therapeutic trials in CY 2018, and 12,752 Interventional accruals of which 4,197 are therapeutic during the current reporting period. CPDM leadership was modified in 2018 with the appointment of Antoinette Wozniak, MD as the Associate Director (AD) for Clinical Research. Dr. Jason Luke has subsequently taken over as the AD for Clinical Research in 2023. Also new in 2018, Bhanu Pappu, PhD, MHA, joined as the AD for Clinical Research Operations and provides day-to-day administrative oversight of CRS and executes the strategic plan. Ms. Kristin Bialobok arrived in 2024 to assume this role after Dr. Pappuâs departure. Focus remains on streamlining processes, new initiatives to decrease clinical trial activation times, increased staff retention, allocated CPDM staff based on trial complexity, strengthened internal audit processes, and enhanced collaborations with the expansive UPMC community oncology practices. Data and Safety Monitoring is an integral part of the CPDM and is supported by the internal audit team as well as the Education and Compliance Office of the University of Pittsburgh. An independent safety team ensures that all disease or modality centers (DMC) across HCC follow the same SOPs for patient safety reporting.

View original record on NIH RePORTER →